--- title: "PureTech Health (NASDAQ:PRTC) Stock Price Up 2.5% - What's Next?" description: "PureTech Health (NASDAQ:PRTC) shares rose 2.5% to $18.25 during trading, with a notable increase in volume. A hedge fund, Millennium Management LLC, recently acquired 45,264 shares valued at approxima" type: "news" locale: "en" url: "https://longbridge.com/en/news/230601245.md" published_at: "2025-03-05T05:52:29.000Z" --- # PureTech Health (NASDAQ:PRTC) Stock Price Up 2.5% - What's Next? > PureTech Health (NASDAQ:PRTC) shares rose 2.5% to $18.25 during trading, with a notable increase in volume. A hedge fund, Millennium Management LLC, recently acquired 45,264 shares valued at approximately $823,000. The company is focused on developing biotechnology solutions, including treatments for idiopathic pulmonary fibrosis and solid tumors. Despite a Strong Buy rating, analysts suggest there are better investment options available. PureTech Health plc (NASDAQ:PRTC - Get Free Report) rose 2.5% during trading on Monday . The stock traded as high as $18.53 and last traded at $18.25. Approximately 3,307 shares traded hands during mid-day trading, an increase of 30% from the average daily volume of 2,553 shares. The stock had previously closed at $17.80. Get **PureTech Health** alerts: ## PureTech Health Stock Up 2.5 % The firm has a 50 day simple moving average of $18.55 and a 200 day simple moving average of $20.20. ## Institutional Inflows and Outflows A hedge fund recently bought a new stake in PureTech Health stock. Millennium Management LLC bought a new position in PureTech Health plc (NASDAQ:PRTC - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 45,264 shares of the company's stock, valued at approximately $823,000. Millennium Management LLC owned 0.19% of PureTech Health as of its most recent SEC filing. Institutional investors own 0.04% of the company's stock. ## About PureTech Health (Get Free Report) PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies. ## Featured Stories - Five stocks we like better than PureTech Health - How to start investing in penny stocks - Bearish Investors Can Seek Refuge in Recession-Resistant ETFs - Short Selling: How to Short a Stock - 3 Oversold Magnificent Seven Stocks at Key Levels: Buy Now? - Market Cap Calculator: How to Calculate Market Cap - 3M to Hit $175 by Mid-Year, and Higher Highs Are Likely *This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.* ## Should You Invest $1,000 in PureTech Health Right Now? Before you consider PureTech Health, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and PureTech Health wasn't on the list. While PureTech Health currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys. View The Five Stocks Here ### Related Stocks - [PRTC.US - PureTech Health](https://longbridge.com/en/quote/PRTC.US.md) ## Related News & Research | Title | Description | URL | |-------|-------------|-----| | PureTech Health PLC 贊助的美國存託憑證（NASDAQ:PRTC）空頭頭寸最新動態 | PureTech Health PLC（納斯達克代碼：PRTC）在 1 月份的空頭頭寸減少了 18.8%，截至 1 月 30 日，共有 3,860 股被賣空。根據平均交易量 3,245 股，目前的空頭頭寸比率為 1.2 天。該股票交易價格為 | [Link](https://longbridge.com/en/news/276082967.md) | | PureTech 的 Deupirfenidone 獲得美國 FDA 和歐盟的孤兒藥資格，用於治療肺纖維化 | PureTech Health PLC：PURETECH 宣佈美國食品藥品監督管理局和歐洲委員會授予 DEUPIRFENIDONE（LYT-100）在特發性肺纖維化中的孤兒藥資格 | [Link](https://longbridge.com/en/news/276363780.md) | | 美股「黑幕」：10b5-1 計劃漏洞是否合法內幕交易｜藍血工廠 | 美國的 Governance 存在漏洞，ADM 因會計問題被 SEC 調查並罰款 4000 萬美元。CEO 在股價高位時利用 10b5-1 計劃拋售近 2000 萬美元股票，成功避開股價下跌。此類操作並非個案，EBS 公司 CEO 在疫苗汙 | [Link](https://longbridge.com/en/news/275224827.md) | | Virtuix 將在2026年3月4日星期三敲響納斯達克收盤鍾 \| VTIX 股票新聞 | Virtuix Inc.（納斯達克代碼：VTIX）將在 2026 年 3 月 4 日敲響納斯達克收盤鍾，以慶祝其最近的上市。首席執行官 Jan Goetgeluk 強調了這一里程碑對公司及其股東的重要性。該活動將進行現場直播，管理層將在 2 | [Link](https://longbridge.com/en/news/276334161.md) | | IDEAYA 第四季度的利潤略高於預期 | IDEAYA 第四季度的收益略微超出分析師預期，每股收益為-0.94 美元，而市場共識為-0.97 美元。該公司報告的淨收入為-8327 萬美元，同樣超出預期。合作收入同比增長，IDEAYA 預計將在 3 月底之前公佈其轉移性葡萄膜黑色素瘤 | [Link](https://longbridge.com/en/news/276114938.md) | --- > **Disclaimer**: This article is for reference only and does not constitute any investment advice.